{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:57:49Z","timestamp":1768352269406,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00192-022-05271-w","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T13:13:42Z","timestamp":1657026822000},"page":"2421-2426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prevalence of pelvic floor disorders, associations of endocrine therapy, and surgical intervention among breast cancer survivors"],"prefix":"10.1007","volume":"33","author":[{"given":"Jon F.","family":"Pennycuff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Desale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee A.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"5271_CR1","unstructured":"Breast Cancer Facts and Figures 2020. American Cancer Society. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/breast-cancer-facts-andfigures\/breast-cancer-facts-and-figures-2019-2020.pdf"},{"issue":"5","key":"5271_CR2","doi-asserted-by":"publisher","first-page":"485e1","DOI":"10.1016\/j.ajog.2010.01.074","volume":"202","author":"A Shahryarinejad","year":"2010","unstructured":"Shahryarinejad A, Gardner TR, Cline JM, Levine WN, Bunting HA, Brodman MD, Ascher-Walsh CJ, Scotti RJ, Vardy MD. Effect of hormone replacement and selective estrogen receptor modulators (SERMs) on the biomechanics and biochemistry of pelvic support ligaments in the\u00a0cynomolgus\u00a0monkey (Macaca\u00a0fascicularis). AJOG. 2010;202(5):485e1\u20139.","journal-title":"AJOG"},{"issue":"5","key":"5271_CR3","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/j.ajog.2004.10.639","volume":"192","author":"MD Vardy","year":"2005","unstructured":"Vardy MD, Gardner TR, Cosman F, Scotti RJ, Mikhail MS, Preiss-Bloom AO, Williams JK, Cline JM, Lindsay R. The effects of hormone replacement on the biomechanical properties of the uterosacral and round ligaments in the monkey model. AJOG. 2005;192(5):1741\u201351.","journal-title":"AJOG"},{"issue":"10","key":"5271_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1200\/JCO.1984.2.10.1102","volume":"2","author":"GM Clark","year":"1984","unstructured":"Clark GM, Osborne CK, McGuire WL. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984;2(10):1102\u20139.","journal-title":"J Clin Oncol"},{"key":"5271_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/jnci\/95.7.526","volume":"95","author":"AN Freedman","year":"2003","unstructured":"Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of U.S. women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"5271_CR6","unstructured":"Cancer Treatment & Survivorship Facts & Figures 2019 \u2013 2021. American Cancer Society. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/cancer-treatment-and-survivorship-facts-and-figures\/cancer-treatment-and-survivorship-facts-and-figures-2019-2021.pdf. Access 27 Jan\u00a02021."},{"issue":"3","key":"5271_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/13697130500117946","volume":"8","author":"P Albertazzi","year":"2005","unstructured":"Albertazzi P, Sharma S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric. 2005;8(3):214\u201320.","journal-title":"Climacteric"},{"issue":"3","key":"5271_CR8","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/13697130701379311","volume":"10","author":"S Sharma","year":"2007","unstructured":"Sharma S, Albetazzi P, Bottazi M. The long-term effect of\u00a0raloxifene\u00a0on the genitourinary tract. Climacteric. 2007;10(3):244\u20138.","journal-title":"Climacteric"},{"issue":"11","key":"5271_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s10552-016-0810-x","volume":"27","author":"SN Landi","year":"2016","unstructured":"Landi SN, Doll KM, Bensen JT, Hendrix L, Anders CK, Wu JM, Nichols HB. Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis. Cancer Causes Control. 2016;27(11):1325\u201332.","journal-title":"Cancer Causes Control"},{"issue":"3","key":"5271_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cncr.26324","volume":"118","author":"KA Donovan","year":"2012","unstructured":"Donovan KA, Boyington AR, Ismail-Khan R, Wyman J. Urinary symptoms in breast cancer: a systematic review. Cancer. 2012;118(3):582\u201393.","journal-title":"Cancer"},{"issue":"3","key":"5271_CR11","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3747\/co.26.4787","volume":"26","author":"K Bilodeau","year":"2019","unstructured":"Bilodeau K, Tremblay D, Durand MJ. Gaps and delays in survivorship care in the return=to=work pathway for survivors of breast cancer-a qualitative study. Curr Oncol. 2019;26(3):414\u20137.","journal-title":"Curr Oncol"},{"key":"5271_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1067\/mob.2003.374","volume":"189","author":"MD Vardy","year":"2003","unstructured":"Vardy MD, Lindsay R, Scott RJ, et al. Short-term urogenital effects of\u00a0raloxifene, tamoxifen, and estrogen. Am J Obstet Gynecol. 2003;189:81\u20138.","journal-title":"Am J Obstet Gynecol"},{"key":"5271_CR13","first-page":"558","volume":"93","author":"GC Davies","year":"1999","unstructured":"Davies GC, Huster WJ, Lu Y, Plouffe L, Lakshmann M. Adverse events reported by postmenopausal women in controlled trials with\u00a0raloxifene. Obstet Gynecol. 1999;93:558\u201365.","journal-title":"Obstet Gynecol"},{"key":"5271_CR14","first-page":"91","volume":"98","author":"SR Goldstein","year":"2001","unstructured":"Goldstein SR, Neven P, Zhour U, Taylor YU, Ciaccia AV, Plouffe L. Raloxifene\u00a0effect on frequency of surgery for pelvic floor relaxation. Obstet\u00a0Gynecol. 2001;98:91\u20136.","journal-title":"Obstet\u00a0Gynecol"},{"key":"5271_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/1471-2407-13-377","volume":"13","author":"AJ White","year":"2013","unstructured":"White AJ, Reeve BB, Chen RC, et al. Urinary incontinence and health-related quality of life among older Americans with and without cancer: a cross-sectional study. BMC Cancer. 2013;13:377.","journal-title":"BMC Cancer"},{"key":"5271_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jnci\/94.1.39","volume":"94","author":"PA Ganz","year":"2002","unstructured":"Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst. 2002;94:39\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"5271_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/01.AOG.0000109429.67671.d1","volume":"103","author":"LE Waetjen","year":"2004","unstructured":"Waetjen LE, Brown JS, Modelska K, Blackwell T, Vittinghoff E, Cummings SR. Effect of\u00a0raloxifene\u00a0on urinary incontinence: a randomized controlled trial. Obstet Gynecol. 2004;103:261\u20136.","journal-title":"Obstet Gynecol"},{"key":"5271_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1054\/bjoc.2001.1703","volume":"84","author":"MB Marttunen","year":"2000","unstructured":"Marttunen MB, Cacciatore B, Hietanen P, et al. Prospective study on\u00a0gynaecological\u00a0effects of two antiestrogens tamoxifen and\u00a0toremifene\u00a0in postmenopausal women. Br J Cancer. 2000;84:897\u2013902.","journal-title":"Br J Cancer"},{"issue":"8","key":"5271_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","volume":"15","author":"L Morales","year":"2004","unstructured":"Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anti-Cancer Drugs. 2004;15(8):753\u201360.","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"5271_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/AOG.0000000000000057","volume":"123","author":"JM Wu","year":"2014","unstructured":"Wu JM, Vaughan CP, Goode PS, et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstet Gynecol. 2014;123(1):141\u20138.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"5271_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s10549-011-1801-y","volume":"131","author":"U Guth","year":"2012","unstructured":"Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM. Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat. 2012;131(2):491\u20139.","journal-title":"Breast Cancer Res Treat"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-022-05271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-022-05271-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-022-05271-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T15:36:53Z","timestamp":1661873813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-022-05271-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["5271"],"URL":"https:\/\/doi.org\/10.1007\/s00192-022-05271-w","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"10 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}